High expression of TIM3, an inhibitory immune checkpoint receptor, on CD8 + T cells has been associated with tumor progression and poor outcomes (Roussel et al., 2021; Xu-Monette et al., 2019). This evidence concerns the gene CD8A and neoplasm.